One point in discussion of real world vs. trial SVRs that people seem to miss is that phama sponsors (esp., the size of GILD and ABBV) get to choose their trial sites and investigators. You can bet that ABBV had selected investigators that are comfortable with managing complex regimens including ritonavir (i.e., investigator mix is skewed toward IDs and perhaps even "advanced" IDs). The general community Gastro may not be as good at keeping discontinuation rates at single digits and compliance rates sufficiently high.
Market Data 
Markets 
AI
